Patents Represented by Attorney, Agent or Law Firm James M. Bogden
-
Patent number: 6828419Abstract: The present invention relates to polynucleotide and polypeptide molecules for zsig63, a novel secreted salivary protein. The polypeptides, and polynucleotides encoding them, may exhibit anti-microbial activity and may be used in the study or treatment of microbial infections. The polynucleotides encoding zsig63, are located on chromosome 4, and can be used to identify a region of the genome associated with human disease states. The present invention also includes antibodies to the zsig63 polypeptides.Type: GrantFiled: August 3, 2001Date of Patent: December 7, 2004Assignee: ZymoGenetics, Inc.Inventors: David A. Adler, Paul O. Sheppard
-
Patent number: 6761882Abstract: Novel cytokine polypeptides, materials and methods for making them, and method of use are disclosed. The polypeptides comprise at least nine contiguous amino acid residues of SEQ ID NO:2 or SEQ ID NO:4, and may be prepared as polypeptide fusions comprise heterologous sequences, such as affinity tags. The polypeptides and polynucleotides encoding them may be used within a variety of therapeutic, diagnostic, and research applications.Type: GrantFiled: May 2, 2002Date of Patent: July 13, 2004Assignee: ZymoGenetics, Inc.Inventors: Darrell C. Conklin, Zeren Gao
-
Patent number: 6756214Abstract: Novel polypeptides, polynucleotides encoding them, materials and methods for making them, antibodies that specifically bind to them, and methods of using the polypeptides, polynucleotides, and antibodies are disclosed. The polypeptides comprise at least nine contiguous amino acid residues of SEQ ID NO:2 or SEQ ID NO:5, and may be prepared as polypeptide fusions comprising heterologous sequences, such as affinity tags. The polypeptides and polynucleotides encoding them may be used within a variety of therepeutic, diagnostic, and research applications, including in vitro diagnosis and in vivo imaging of cancers and other sites of abnormal cell proliferation.Type: GrantFiled: November 8, 2001Date of Patent: June 29, 2004Assignee: ZymoGenetics, Inc.Inventors: Darrell C. Conklin, Zeren Gao
-
Patent number: 6750045Abstract: A yeast fermentation medium that does not contain yeast cell extract but is comprised of a mixture of oleic acid, lactic acid and palmitic acid. Using this fermentation medium yields of factor XIII were increased 250%.Type: GrantFiled: July 23, 2002Date of Patent: June 15, 2004Assignee: ZymoGenetics, Inc.Inventor: Bruce L. Zamost
-
Patent number: 6214345Abstract: The present invention relates to drug-ligand conjugates wherein the drug is linked to the ligand through a protein peptide linker and a connector, a process for the preparation of the conjugates, method of controlling the growth of undesirable cells, pharmaceutical compositions, and intermediates thereof.Type: GrantFiled: May 14, 1993Date of Patent: April 10, 2001Assignee: Bristol-Myers Squibb Co.Inventors: Raymond Armand Firestone, Gene Michael Dubowchik
-
Patent number: 5922596Abstract: An isolated DNA sequence capable of directing gene expression comprising a hRAR-.alpha. promoter or a hRAR-.alpha. promoter element, expression vectors containing the DNA sequence and host cells containing the expression vectors.Type: GrantFiled: December 10, 1990Date of Patent: July 13, 1999Assignee: Bristol-Myers Squibb Co.Inventors: Pierre Chambon, Nigel J. Brand, Martin Petkovich
-
Patent number: 5919650Abstract: Method for inactivating the function produced by a protein using an intracellularly expressed antibody or fragment thereof.Type: GrantFiled: April 22, 1990Date of Patent: July 6, 1999Assignee: Bristol-Myers Squibb Co.Inventors: Mariano Barbacid, Ximena Montano
-
Patent number: 5789197Abstract: Nucleic acid sequences, particularly DNA sequences, coding for all or part of the high molecular weight subunit of microsomal triglyceride transfer protein, expression vectors containing the DNA sequences, host cells containing the expression vectors, and methods utilizing these materials. The invention also concerns polypeptide molecules comprising all or part of the high molecular weight subunit of microsomal triglyceride transfer protein, and methods for producing these polypeptide molecules. The invention additionally concerns novel methods for preventing, stabilizing or causing regression of atherosclerosis and therapeutic agents having such activity. The invention concerns further novel methods for lowering serum liquid levels and therapeutic agents having such activity.Type: GrantFiled: June 7, 1995Date of Patent: August 4, 1998Assignee: E. R. Squibb & Sons, Inc.Inventors: John R. Wetterau, II, Daru Young Sharp, Richard E. Gregg
-
Patent number: 5736536Abstract: A novel method for preventing, stabilizing or causing regression of vascular leak syndrome is disclosed. The method comprises administering to a patient in need thereof a compound selected from the group consisting of a corticosteroid, a non-steroidal anti-inflammatory agent, 15-deoxyspergualin and related compounds, and phospholipase A.sub.2 inhibitors.Type: GrantFiled: February 6, 1997Date of Patent: April 7, 1998Assignee: Bristol-Myers Squibb CompanyInventors: Clay Siegall, Dana Chace
-
Patent number: 5688781Abstract: A novel method for preventing, stabilizing or causing regression of vascular leak syndrome is disclosed. The method comprises administering to a patient in need thereof a compound selected from the group consisting of a corticosteroid, a non-steroidal anti-inflammatory agent, 15-deoxyspergualin and related compounds, and phospholipase A.sub.2 inhibitors.Type: GrantFiled: August 19, 1994Date of Patent: November 18, 1997Assignee: Bristol-Myers Squibb CompanyInventors: Clay Siegall, Dana Chace
-
Patent number: 5667987Abstract: Nucleic acid sequences, particularly DNA sequences, coding for all or part of p53 response protein PIGI-1, expression vectors containing the DNA sequences, host cells containing the expression vectors, and methods utilizing these materials are disclosed. The invention also concerns polypeptide molecules comprising all or part of p53 response protein PIGI-1, and methods for producing these polypeptide molecules.Type: GrantFiled: July 12, 1994Date of Patent: September 16, 1997Assignee: Bristol-Myers Squibb CompanyInventors: Leonard Buckbinder, Randy Talbott, Bernd R. Seizinger, Nikolai Kley
-
Patent number: 5595872Abstract: Nucleic acid sequences, particularly DNA sequences, coding for all or part of the high molecular weight subunit of microsomal triglyceride transfer protein, expression vectors containing the DNA sequences, host cells containing the expression vectors, and methods utilizing these materials. The invention also concerns polypeptide molecules comprising all or part of the high molecular weight subunit of microsomal triglyceride transfer protein, and methods for producing these polypeptide molecules. The invention additionally concerns novel methods for preventing, stabilizing or causing regression of atherosclerosis and therapeutic agents having such activity. The invention concerns further novel methods for lowering serum liquid levels and therapeutic agents having such activity.Type: GrantFiled: September 3, 1993Date of Patent: January 21, 1997Assignee: Bristol-Myers Squibb CompanyInventors: John R. Wetterau, II, Daru Y. Sharp, Richard E. Gregg, Scott A. Biller, John K. Dickson, R. Michael Lawrence, John E. Lawson, Henry M. Holava, Richard A. Partyka
-
Patent number: 5589372Abstract: Nucleic acid sequences, particularly DNA sequences, coding for all or part of a squalene synthetase, expression vectors containing the DNA sequences, host cells containing the expression vectors, and methods utilizing these materials. The invention also concerns polypeptide molecules comprising all or part of a squalene synthetase, and methods for producing these polypeptide molecules.Type: GrantFiled: December 8, 1994Date of Patent: December 31, 1996Assignee: E. R. Squibb & Sons, Inc.Inventor: Gordon W. Robinson
-
Patent number: 5556747Abstract: A method for site-directed mutagenesis using a third mutagenic primer in a polymerase chain reaction (PCR) based methodology.Type: GrantFiled: July 9, 1990Date of Patent: September 17, 1996Assignee: E. R. Squibb & Sons, Inc.Inventor: Ramesh Kumar
-
Patent number: 5185248Abstract: Assays for farnesyl-protein transferase (FT) which can be used to identify substances that block the farnesylation of ras oncogene products are described. Because farnesylation is required for ras oncogene activity, inhibitory compounds identified in the assays of the invention can block neoplastic transformation mediated by the ras oncogene. The assays of the invention are targeted for a step subsequent to the synthesis of farnesyl pyrophosphate (FPP), the donor of the farnesyl residue, and an intermediate in cholesterol synthesis and other important cellular pathways. Therefore, compounds which inhibit ras mediated transformation, yet do not cause major disruptions of important cell pathways that require FPP as an intermediate may be identified using the assays of the invention.Type: GrantFiled: May 8, 1990Date of Patent: February 9, 1993Assignee: E. R. Squibb & Sons, Inc.Inventors: Mariano Barbacid, Veeraswamy Manne
-
Patent number: 5151504Abstract: An improved method for the purification of monoclonal antibodies using Protein G, whereby the monoclonal antibodies are eluted from the Protein G at alkaline pH.Type: GrantFiled: March 26, 1990Date of Patent: September 29, 1992Assignee: E. R. Squibb & Sons, Inc.Inventor: Edward M. Croze
-
Patent number: 5141865Abstract: Monoclonal antibodies which bind thromboxane A2 receptor antagonists, hybrid cell lines which produce these monoclonal antibodies, and immunoassay methods for detecting thromboxane A2 receptor antagonists using these monoclonal antibodies.Type: GrantFiled: November 17, 1989Date of Patent: August 25, 1992Assignee: E. R. Squibb & Sons, Inc.Inventors: Edward M. Croze, Jan-I Tu
-
Patent number: 5120639Abstract: Two peptides, P6 and P7, having the amino acid sequence APGDEPAPPY and AGATAEETRY have been used to obtain antibodies made against them, which antibodies specifically neutralize HSV-1 and HSV-2 DNA polymerase. The present invention also contemplates a method of screening for inhibitors of HSV-1 and HSV-2 polymerase utilizing the antibodies.Type: GrantFiled: April 3, 1989Date of Patent: June 9, 1992Assignee: E. R. Squibb & Sons, Inc.Inventors: Mary L. Haffey, James T. Matthews